Since the 1960s there has been an increasing trend towards centralisation of the treatment of childhood cancers in Britain. In 1977 the United Kingdom Children's Cancer Study Group (UKCCSG) was formed by a number of consultants specialising in paediatric oncology. Since then there has been a steady increase in membership of the UKCCSG until now nearly every Health Service region in Britain contains a paediatric oncology centre whose senior staff are members of the UKCCSG. This paper describes the increased centralisation of the care of children with cancer since 1977, and compares survival rates for children with some of the principal types of childhood neoplasm who were treated at paediatric oncology centres with those of children treated elsewhere.
Patients and methods
The Childhood Cancer Research Group (CCRG) maintains the national registry of childhood malignant diseases for Great Britain. The primary source of information is notification to the National Cancer Registration schemes for England, Scotland, and Wales; the CCRG receives a copy of the registration of each patient aged under 15 1981-84. This also enabled trends in survival to be examined, allowing for changes in referral patterns. Because older children were less likely to be treated at paediatric oncology centres, age at diagnosis grouped as 0-11 and 12-14 years was allowed for in all the analyses.
In Table 3 shows the three year survival for children in each diagnostic group, categorised by year of diagnosis and treatment centre, together with the results of significance tests for differences in the survival curves among types of treatment centre, allowing for the effects of age and year of diagnosis. Years since diagnosis There was a significant variation in the survival for rhabdomyosarcoma, again with a higher proportion of survivors at paediatric oncology centres (fig 4) . This was true for both age groups and both calendar periods. There The survival analysis showed a much lower survival for patients with acute non-lymphoblastic leukaemia treated at non-teaching hospitals, possibly because they would have had little experience in treating children with this disease. Although the prognosis is still poor, the three year survival of about 26% during 1977-84 was considerably higher than the 10% for 1971-74.12 This improvement is largely attributable to the adoption of more effective chemotherapy, though bone marrow transplantation may have also increased the number of survivors.
By the early 1970s Hodgkin's disease was already one of the childhood cancers with the best prognosis, with a three year survival of over 80%.12
Since then there has been further steady improvement, and nowadays well over 90% of patients survive for at least three years. These improvements are similar to those achieved in adults during the same period.13
There has been a considerable improvement in survival for childhood non-Hodgkin's lymphomas since 1971-74 when the three year survival was only 28% compared with over 65% for patients diagnosed in the 1980s. 12 The adoption of more intensive multiple drug regimens is probably responsible for the greatly improved outlook.14 15 Although survival rates for neuroblastoma are still low in comparison with many other childhood cancers, the prospects are much better than in the early 1970s when long term survival was only 15%. 12 The survival was lower at paediatric oncology centres than elsewhere, maybe because these centres were seeing a much larger proportion of patients with advanced disease. The greater number of patients with stage III and IV tumours at these centres could be an artefact caused by more careful staging than at other hospitals, but this is unlikely as the proportions of patients in these stages at the paediatric oncology centres remained constant between the two calendar periods (at around 19% for stage III and 54% for stage IV), and most of the survivors at other hospitals had localised tumours which were apparently cured without chemotherapy. During the past decade there have been considerable improvements in the treatment of advanced neuroblastomas at specialist centres with encouraging results; more patients have been treated with chemotherapy regimens that include cisplatin and melphalan. 16 Survival rates everywhere were high for Wilms' tumour compared with that of earlier years. Previous reports showed an advantage in survival for patients treated in clinical trials or at specialist centres.5 6 There was no significant difference in survival in the present series between children managed at paediatric oncology centres and those managed elsewhere. Although some of the children in other hospitals have been included in the UKCCSG study and treated using that protocol, however, it seems that others were given more radiotherapy or chemotherapy than was appropriate for their stage and histological subtype within the study. Kramer et al also found no significant differences in survival between cancer centres and other hospitals.9 They suggested that this might be because by the time of their study Wilms' tumour was readily curable by regimens that had been published and were widely used. For certain diagnostic groups, notably acute nonlymphoblastic leukaemia and non-Hodgkin's lymphoma, there was a considerably higher initial mortality at the non-specialist centres, suggesting failure to achieve remission. Despite the exclusion of untreated patients from the survival analyses, a few patients might have been diagnosed too late for referral to a paediatric oncology centre but nevertheless received some treatment at other hospitals. This is unlikely to account for the difference between types of treatment centre, however, because when the analyses were repeated with all children who survived under one month excluded, the significance level of the difference in survival did not change for any diagnostic group.
There have been considerable improvements in recent years in the survival for several types of childhood cancer, presumably resulting from advances in treatment, and the results obtained at specialist paediatric oncology centres have tended to be better than those achieved elsewhere. The results presented here underline the importance of referring patients to specialist centres where they may benefit as early as possible from the latest advances in treatment. In some instances children receive less aggressive treatment than previously, still with a high probability of survival but with a reduced risk of long term sequelae. Centralisation of treatment may result in increased cost to the family17 and a greater workload at the paediatric oncology centres, but these disadvantages can be alleviated by closer cooperation between specialist centres and local hospitals, especially during maintenance therapy.
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